Advans SA SICAR Has Raised EUR 7 million in Capital Commitments from CDC Group

Aug 2008
New York, United States , August, 12 2008 - CDC Group plc ("CDC"), the UK Government-backed private equity emerging markets fund of funds investor, today announces that it has committed EUR 7 million (US$10.5m) to the Advans SA SICAR ("Advans").

Advans is a regulated specialised venture capital company, which invests mainly in greenfield microfinance institutions (MFIs) in Africa and Asia.

CDC signed a Subscription Agreement by which it committed to invest equity in Advans for an amount of EUR 3 million (US$4.5m) to be executed immediately. CDC will also commit an additional EUR 4 million (US$6m) in Advans in anticipation of the second round of fundraising to be organised by Advans in early 2009.

CDC's investment will support Advans in extending its network of MFIs mainly in Asia and Africa.



Research Analysis Tools

The fund indexes, institution benchmarks and other market information displayed here are all Symbiotics designed analysis tools, created in-house by our analysts and experts. Symbiotics has one of the oldest track records in microfinance investment analysis dating back to the late 1990s; its indexes and benchmarks have been regularly used as markers by investors, asset managers, financial institutions and practitioners. These, as well as several other research products, are available through the Research Account. Click on the link below to find out more.

Learn More